Trials / Completed
CompletedNCT04959110
Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Chulalongkorn University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Citrate has been proposed as anticoagulation of choice in continuous renal replacement therapy (CRRT). However, little is known about the pharmacokinetics (PKs) and metabolism of citrate in liver failure patients who require CRRT with regional citrate anticoagulation (RCA).
Detailed description
This study aimed to evaluate citrate PKs, metabolic complications, and clinical outcomes among critically ill acute liver failure (ALF) and acute on top chronic liver failure (ACLF) patients receiving CRRT.
Conditions
- Citrate Toxicity
- Regional Citrate Anticoagulation
- Liver Failure, Acute
- Liver Failure, Acute on Chronic
- Pharmacokinetic
- Continuous Renal Replacement Therapy
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Pharmacokinetic study | * Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L * Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium * In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter |
Timeline
- Start date
- 2019-07-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2021-07-13
- Last updated
- 2022-11-14
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT04959110. Inclusion in this directory is not an endorsement.